WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 530324
CAS#: 359714-55-9
Description: CAY10499 is a potent and selective monoglyceride lipase inhibitor exhibiting an IC50 of 90 nM for the recombinant enzyme.
MedKoo Cat#: 530324
Name: CAY10499
CAS#: 359714-55-9
Chemical Formula: C18H17N3O5
Exact Mass: 355.1168
Molecular Weight: 355.35
Elemental Analysis: C, 60.84; H, 4.82; N, 11.83; O, 22.51
Synonym: CAY10499; CAY-10499; CAY 10499.
IUPAC/Chemical Name: [4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2-methylphenyl]-carbamic acid, phenylmethyl ester
InChi Key: QTENHWTVRQKWRI-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H17N3O5/c1-12-10-14(21-18(23)26-17(20-21)24-2)8-9-15(12)19-16(22)25-11-13-6-4-3-5-7-13/h3-10H,11H2,1-2H3,(H,19,22)
SMILES Code: O=C(OCC1=CC=CC=C1)NC2=CC=C(N3C(OC(OC)=N3)=O)C=C2C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 355.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Iglesias J, Lamontagne J, Erb H, Gezzar S, Zhao S, Joly E, Truong VL, Skorey K, Crane S, Madiraju SR, Prentki M. Simplified assays of lipolysis enzymes for drug discovery and specificity assessment of known inhibitors. J Lipid Res. 2016 Jan;57(1):131-41. doi: 10.1194/jlr.D058438. PubMed PMID: 26423520; PubMed Central PMCID: PMC4689331.
2: Del Carlo S, Manera C, Chicca A, Arena C, Bertini S, Burgalassi S, Tampucci S, Gertsch J, Macchia M, Saccomanni G. Development of an HPLC/UV assay for the evaluation of inhibitors of human recombinant monoacylglycerol lipase. J Pharm Biomed Anal. 2015 Apr 10;108:113-21. doi: 10.1016/j.jpba.2015.02.007. PubMed PMID: 25743577.
3: Mita T, Furuhashi M, Hiramitsu S, Ishii J, Hoshina K, Ishimura S, Fuseya T, Watanabe Y, Tanaka M, Ohno K, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Shimamoto K, Miura T. FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver Spring). 2015 Feb;23(2):359-67. doi: 10.1002/oby.20954. PubMed PMID: 25521833.
4: Manna PR, Cohen-Tannoudji J, Counis R, Garner CW, Huhtaniemi I, Kraemer FB, Stocco DM. Mechanisms of action of hormone-sensitive lipase in mouse Leydig cells: its role in the regulation of the steroidogenic acute regulatory protein. J Biol Chem. 2013 Mar 22;288(12):8505-18. doi: 10.1074/jbc.M112.417873. PubMed PMID: 23362264; PubMed Central PMCID: PMC3605665.
5: Wan Z, Matravadia S, Holloway GP, Wright DC. FAT/CD36 regulates PEPCK expression in adipose tissue. Am J Physiol Cell Physiol. 2013 Mar 1;304(5):C478-84. doi: 10.1152/ajpcell.00372.2012. PubMed PMID: 23302781.
6: Matuszak N, Hamtiaux L, Baldeyroux B, Muccioli GG, Poupaert JH, Lansiaux A, Lambert DM. Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth. Eur J Pharm Sci. 2012 Feb 14;45(3):263-71. doi: 10.1016/j.ejps.2011.11.011. PubMed PMID: 22127371.
7: Grisouard J, Bouillet E, Timper K, Radimerski T, Dembinski K, Frey DM, Peterli R, Zulewski H, Keller U, Müller B, Christ-Crain M. Both inflammatory and classical lipolytic pathways are involved in lipopolysaccharide-induced lipolysis in human adipocytes. Innate Immun. 2012 Feb;18(1):25-34. doi: 10.1177/1753425910386632. PubMed PMID: 21088047.
8: Holtfrerich A, Makharadze T, Lehr M. High-performance liquid chromatography assay with fluorescence detection for the evaluation of inhibitors against human recombinant monoacylglycerol lipase. Anal Biochem. 2010 Apr 15;399(2):218-24. doi: 10.1016/j.ab.2009.12.015. PubMed PMID: 20015447.
9: Savinainen JR, Yoshino M, Minkkilä A, Nevalainen T, Laitinen JT. Characterization of binding properties of monoglyceride lipase inhibitors by a versatile fluorescence-based technique. Anal Biochem. 2010 Apr 1;399(1):132-4. doi: 10.1016/j.ab.2009.12.009. PubMed PMID: 20005861.
10: Minkkilä A, Savinainen JR, Käsnänen H, Xhaard H, Nevalainen T, Laitinen JT, Poso A, Leppänen J, Saario SM. Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors. ChemMedChem. 2009 Aug;4(8):1253-9. doi: 10.1002/cmdc.200900137. PubMed PMID: 19472270.
11: Muccioli GG, Labar G, Lambert DM. CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. Chembiochem. 2008 Nov 3;9(16):2704-10. doi: 10.1002/cbic.200800428. PubMed PMID: 18855964.
